Related Experiment Video
Updated: Aug 11, 2026
Isolation of Cortical Microglia with Preserved Immunophenotype and Functionality From Murine Neonates
Published on: January 30, 2014
Drug Development for Alzheimer's Disease: Microglia Induced Neuroinflammation as a Target?
Yuan Dong1, Xiaoheng Li2, Jinbo Cheng3
1Department of Biochemistry, Medical College, Qingdao University, Qingdao 266071, China. juliadong829@hotmail.com.
Abstract:
Alzheimer's disease (AD) is one of the most common causes of dementia. Its pathogenesis is characterized by the aggregation of the amyloid-β (Aβ) protein in senile plaques and the hyperphosphorylated tau protein in neurofibrillary tangles in the brain. Current medications for AD can provide temporary help with the memory symptoms and other cognitive changes of patients, however, they are not able to stop or reverse the progression of AD. New medication discovery and the development of a cure for AD is urgently in need. In this review, we summarized drugs for AD treatments and their recent updates, and discussed the potential of microglia induced neuroinflammation as a target for anti-AD drug development.
Insights
Alzheimer's disease (AD) treatments offer temporary symptom relief but cannot halt progression. This review explores current AD drugs and highlights microglia-targeted neuroinflammation as a promising avenue for new therapies.
Area of Science:
- Neuroscience
- Pharmacology
- Pathology
Background:
- Alzheimer's disease (AD) is a leading cause of dementia.
- AD pathogenesis involves amyloid-beta (Aβ) plaques and tau tangles.
- Existing AD medications provide only symptomatic relief, not disease modification.
Purpose of the Study:
- To review current drugs for Alzheimer's disease (AD) and their recent advancements.
- To discuss the potential of targeting microglia-induced neuroinflammation for novel anti-AD drug development.
Main Methods:
- Comprehensive literature review of existing AD treatments.
- Analysis of recent updates in pharmacological interventions for AD.
- Exploration of neuroinflammation and microglial pathways in AD pathogenesis.
Main Results:
- Current AD medications offer limited efficacy in altering disease progression.
- Neuroinflammation, particularly microglia-mediated, is increasingly recognized as a key factor in AD.
- Targeting microglial pathways presents a novel therapeutic strategy for AD.
Conclusions:
- There is an urgent need for new drugs capable of halting or reversing AD.
- Modulating neuroinflammation offers a promising therapeutic target for developing effective anti-AD treatments.
- Further research into microglia-targeted therapies is warranted for Alzheimer's disease (AD) drug development.
Related Concept Videos
01:26Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment